Literature DB >> 34969818

Disarming the Old Foe. Restoring T-Cell Immune Function with mTor-Inhibitors to Tackle Cytomegalovirus Infection.

Oriol Bestard1, Elena Crespo2.   

Abstract

Entities:  

Keywords:  cytomegalovirus; immunology and pathology; kidney transplantation

Mesh：

Substances：

Year:  2022        PMID： 34969818      PMCID： PMC8763183          DOI： 10.1681/ASN.2021111471

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  11 in total

1.  Cellular Immunity to Predict the Risk of Cytomegalovirus Infection in Kidney Transplantation: A Prospective, Interventional, Multicenter Clinical Trial.

Authors:  Marta Jarque; Elena Crespo; Edoardo Melilli; Alex Gutiérrez; Francesc Moreso; Lluís Guirado; Ignacio Revuelta; Nuria Montero; Joan Torras; Lluís Riera; Maria Meneghini; Omar Taco; Anna Manonelles; Javier Paul; Daniel Seron; Carme Facundo; Josep M Cruzado; Salvador Gil Vernet; Josep M Grinyó; Oriol Bestard
Journal:  Clin Infect Dis       Date:  2020-12-03       Impact factor: 9.079

2.  An Interventional Study Using Cell-Mediated Immunity to Personalize Therapy for Cytomegalovirus Infection After Transplantation.

Authors:  D Kumar; M Mian; L Singer; A Humar
Journal:  Am J Transplant       Date:  2017-06-16       Impact factor: 8.086

Review 3.  Epidemiology, risk factors, and outcomes associated with cytomegalovirus in adult kidney transplant recipients: A systematic literature review of real-world evidence.

Authors:  Amit D Raval; Kristin D Kistler; Yuexin Tang; Yoshihiko Murata; David R Snydman
Journal:  Transpl Infect Dis       Date:  2020-10-22       Impact factor: 2.228

Review 4.  Modulation of innate and adaptive immunity by cytomegaloviruses.

Authors:  Richard Berry; Gabrielle M Watson; Stipan Jonjic; Mariapia A Degli-Esposti; Jamie Rossjohn
Journal:  Nat Rev Immunol       Date:  2019-10-30       Impact factor: 53.106

5.  Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.

Authors:  H Tedesco-Silva; C Felipe; A Ferreira; M Cristelli; N Oliveira; T Sandes-Freitas; W Aguiar; E Campos; M Gerbase-DeLima; M Franco; J Medina-Pestana
Journal:  Am J Transplant       Date:  2015-05-18       Impact factor: 8.086

6.  The changing role of mTOR kinase in the maintenance of protein synthesis during human cytomegalovirus infection.

Authors:  Amy J Clippinger; Tobi G Maguire; James C Alwine
Journal:  J Virol       Date:  2011-02-09       Impact factor: 5.103

7.  TORC1 inhibition enhances immune function and reduces infections in the elderly.

Authors:  Joan B Mannick; Melody Morris; Hans-Ulrich P Hockey; Guglielmo Roma; Martin Beibel; Kenneth Kulmatycki; Mollie Watkins; Tea Shavlakadze; Weihua Zhou; Dean Quinn; David J Glass; Lloyd B Klickstein
Journal:  Sci Transl Med       Date:  2018-07-11       Impact factor: 17.956

8.  mTOR Inhibitors Prevent CMV Infection through the Restoration of Functional αβ and γδ T cells in Kidney Transplantation.

Authors:  Hannah Kaminski; Gabriel Marseres; Nathalie Yared; Marie-Julie Nokin; Vincent Pitard; Atika Zouine; Isabelle Garrigue; Séverine Loizon; Myriam Capone; Xavier Gauthereau; Maria Mamani-Matsuda; Roxane Coueron; Raúl V Durán; Benoît Pinson; Isabelle Pellegrin; Rodolphe Thiébaut; Lionel Couzi; Pierre Merville; Julie Déchanet-Merville
Journal:  J Am Soc Nephrol       Date:  2021-11-01       Impact factor: 10.121

Review 9.  Direct and Indirect Effects of Cytomegalovirus-Induced γδ T Cells after Kidney Transplantation.

Authors:  Lionel Couzi; Vincent Pitard; Jean-François Moreau; Pierre Merville; Julie Déchanet-Merville
Journal:  Front Immunol       Date:  2015-01-21       Impact factor: 7.561

10.  Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system.

Authors:  Sjoerd Klarenbeek; Chris W Doornebal; Sjors M Kas; Nicola Bonzanni; Jinhyuk Bhin; Tanya M Braumuller; Ingrid van der Heijden; Mark Opdam; Philip C Schouten; Kelly Kersten; Roebi de Bruijn; Daniel Zingg; Julia Yemelyanenko; Lodewyk F A Wessels; Karin E de Visser; Jos Jonkers
Journal:  Oncoimmunology       Date:  2020-02-12       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.